Description: <b>B Vitamin supplement.</b> Helps form red blood cells.<br>
Folic acid (vitamin B9) is converted into tetrahydrofolate (THF) and its derivatives. These folate coenzymes are essential for one‐carbon transfer reactions, which are critical for the synthesis of purines and thymidylate—key components of DNA.<br>
<br>
• Folate Deficiency and ROS: A deficiency in folic acid can exacerbate oxidative stress. Insufficient folate has been linked to increased ROS levels, which are capable of damaging cellular macromolecules, including DNA, proteins, and lipids. This oxidative DNA damage further increases mutation rates and contributes to carcinogenesis.<br>
<br>
The evidence suggests that while adequate dietary folate is important for cancer prevention (by maintaining genomic stability and proper methylation), excessive folate supplementation in individuals with undiagnosed or existing neoplasms might be problematic.<br>
<br>
-supplementation of folate may occur as folic acid, folinic acid or 5-methyltetrahydrofolate (5-MTHF).<br>
-5-MTHF also known as L-methylfolate<br>
-Naturally occurring 5-MTHF has important advantages over synthetic folic acid - it is well absorbed even when gastrointestinal pH is altered and its bioavailability is not affected by metabolic defects<br>
-Use of 5-MTHF also prevents the potential negative effects of unconverted folic acid in the peripheral circulation<br>
-Large RCT meta-analyses generally do not show a moderate increase in overall cancer incidence from folic acid during trial periods.<br>
-High-dose folic acid has a long-running concern about “timing” (before vs after neoplasia), and NIH ODS cautions against >1,000 µg/day from supplements (UL) largely due to masking B12 deficiency and risk-uncertainty contexts.<br>
<br>
-It’s best categorized as a “growth substrate / one-carbon cofactor” with high chemo-interaction relevance, not as a standalone anticancer natural product.<br>
<br>
<p><b>Folic acid, vitamin B9</b> — Folic acid is the synthetic, fully oxidized form of the water-soluble vitamin folate and is used in fortified foods, dietary supplements, deficiency treatment, pregnancy-related neural-tube-defect prevention, and selected oncology protocols. It is a nutritional vitamin and one-carbon metabolic precursor rather than a direct anticancer agent. Standard abbreviations include FA and vitamin B9; the broader term folate includes naturally occurring reduced folates, while 5-methyltetrahydrofolate, folinic acid and folic acid are chemically and clinically distinct forms. After intestinal absorption, folic acid must be reduced by dihydrofolate reductase to tetrahydrofolate derivatives that support purine synthesis, thymidylate synthesis, methionine regeneration and methyl-donor metabolism. In cancer, folate has a dual-context role: adequate status protects normal DNA synthesis and genomic stability, whereas folate availability can also support proliferation of established folate-dependent tumors. Folic acid should therefore be classified primarily as a nutritional one-carbon cofactor with major chemotherapy-interaction relevance, not as a standalone cancer treatment.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Supplies reduced folate cofactors for de novo thymidylate and purine synthesis required for DNA and RNA production.</li>
<li>Supports methionine synthase-dependent homocysteine remethylation and maintenance of methionine and S-adenosylmethionine-dependent methylation reactions.</li>
<li>Corrects folate deficiency, thereby reducing megaloblastic anemia, uracil misincorporation, chromosome instability and deficiency-associated oxidative stress.</li>
<li>Modifies antifolate chemotherapy toxicity and efficacy in a drug-, folate-form- and timing-dependent manner.</li>
<li>Reduces pemetrexed-associated hematologic and gastrointestinal toxicity when administered with vitamin B12 according to the treatment protocol.</li>
<li>Modulates neurologic and vascular effects indirectly through homocysteine reduction, particularly when baseline folate or vitamin B12 status is inadequate.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Folic acid is generally well absorbed and has higher apparent bioavailability than naturally occurring food folates, but it requires enzymatic reduction before entering active one-carbon metabolism. Human dihydrofolate reductase activity is relatively limited and variable; larger or repeated doses can produce circulating unmetabolized folic acid. 5-Methyltetrahydrofolate enters the reduced-folate pool without requiring the initial dihydrofolate reductase steps, but evidence does not justify treating all folate forms as universally interchangeable. Folinic acid is a reduced folate used in specific oncology protocols and is not synonymous with ordinary folic acid supplementation.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Cellular effects attributed to millimolar or high-micromolar folic acid exposure are generally not representative of nutritional systemic exposure. Physiologic effects are more accurately interpreted through intracellular folate sufficiency, enzyme saturation, folate transport, baseline deficiency and long-term one-carbon flux rather than acute direct cytotoxicity. Studies using folic-acid-conjugated nanoparticles evaluate folate-receptor targeting by the carrier and should not be interpreted as evidence that free folic acid has the same anticancer activity.</p>
<p><b>Clinical evidence status:</b> Established clinical use for prevention and treatment of folate deficiency and prevention of neural tube defects; protocol-defined adjunct use with pemetrexed; extensive randomized evidence for homocysteine lowering; mixed and subgroup-dependent evidence for cognitive benefit; no established role as a standalone anticancer therapy. Randomized-trial meta-analyses have generally found no substantial overall increase or decrease in cancer incidence during approximately five years of supplementation, but uncertainty remains regarding dose, duration, baseline status and supplementation after neoplasia is established.</p>
<br>
<h3>Folic Acid Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>One-carbon metabolism and nucleotide synthesis</td>
<td>↑ dTMP and purine synthesis capacity when folate-limited</td>
<td>↑ DNA synthesis, repair and hematopoietic cell production</td>
<td>R, G</td>
<td>Metabolic substrate support</td>
<td>Central biochemical function. Adequate folate protects normal genomic integrity but may also remove a growth constraint in established proliferating tumors.</td>
</tr>
<tr>
<td>2</td>
<td>Thymidylate synthase substrate axis</td>
<td>↑ availability of 5,10-methylene-THF for dTMP synthesis</td>
<td>↓ uracil misincorporation and chromosome breakage when deficiency is corrected</td>
<td>R, G</td>
<td>DNA precursor synthesis</td>
<td>This axis explains both the physiologic requirement for folate and the therapeutic rationale for antifolate drugs.</td>
</tr>
<tr>
<td>3</td>
<td>Methionine cycle and methylation capacity</td>
<td>↔ or altered DNA and histone methylation (context-dependent)</td>
<td>↑ methionine regeneration and methyl-donor homeostasis when folate-deficient</td>
<td>G</td>
<td>Epigenetic and metabolic regulation</td>
<td>Direction of gene-specific methylation effects cannot be generalized across tumor types or folate states.</td>
</tr>
<tr>
<td>4</td>
<td>Homocysteine remethylation</td>
<td>↓ homocysteine when folate-responsive</td>
<td>↓ homocysteine when folate or related B-vitamin status is limiting</td>
<td>G</td>
<td>Systemic metabolic correction</td>
<td>Requires adequate vitamin B12-dependent methionine synthase function. Homocysteine reduction is not itself evidence of anticancer efficacy.</td>
</tr>
<tr>
<td>5</td>
<td>Genomic stability during deficiency correction</td>
<td>↓ deficiency-associated DNA damage, but possible ↑ tumor substrate supply</td>
<td>↓ uracil incorporation, strand breaks and megaloblastic change</td>
<td>G</td>
<td>Deficiency correction</td>
<td>Produces a biologically plausible dual effect depending on whether folate deficiency precedes carcinogenesis or supplementation occurs after tumor establishment.</td>
</tr>
<tr>
<td>6</td>
<td>Oxidative stress during folate deficiency</td>
<td>↔ or ↓ ROS indirectly (context-dependent)</td>
<td>↓ deficiency-associated ROS and oxidative macromolecular injury</td>
<td>G</td>
<td>Secondary redox normalization</td>
<td>Folic acid is not primarily a direct antioxidant. Redox effects are secondary to improved one-carbon metabolism, glutathione-related metabolism and reduced homocysteine stress.</td>
</tr>
<tr>
<td>7</td>
<td>Pemetrexed toxicity modulation</td>
<td>↔ antitumor exposure when protocol supplementation is used</td>
<td>↓ myelosuppression and gastrointestinal toxicity</td>
<td>G</td>
<td>Required supportive supplementation</td>
<td>Oral folic acid plus intramuscular vitamin B12 is standard with pemetrexed. Current labeling specifies 400–1000 µg folic acid daily beginning before treatment and continuing after the final dose.</td>
</tr>
<tr>
<td>8</td>
<td>Methotrexate and reduced-folate interaction</td>
<td>Potential ↓ antifolate effect if folate rescue is incorrectly timed</td>
<td>Folinic acid ↑ rescue of normal tissues after high-dose methotrexate</td>
<td>R</td>
<td>Protocol-dependent rescue</td>
<td>Leucovorin is folinic acid, not folic acid. Rescue timing is critical and should not be generalized to self-directed folic acid supplementation.</td>
</tr>
<tr>
<td>9</td>
<td>Fluoropyrimidine chemosensitization</td>
<td>Folinic acid ↑ stabilization of thymidylate synthase inhibition</td>
<td>↑ gastrointestinal and marrow toxicity risk</td>
<td>R</td>
<td>Chemosensitization</td>
<td>This clinically established interaction involves folinic acid with 5-fluorouracil, not routine nutritional folic acid.</td>
</tr>
<tr>
<td>10</td>
<td>Folate receptor targeting</td>
<td>↑ uptake of folate-conjugated carriers in folate-receptor-positive models</td>
<td>Variable uptake according to receptor expression</td>
<td>P, R</td>
<td>Drug-delivery targeting ligand</td>
<td>Activity of folate-decorated nanoparticles belongs primarily to the payload and delivery system. It is not evidence of direct cytotoxicity by free folic acid.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Effect depends on tumor stage, folate status, dose, folate form and concurrent antifolate therapy</td>
<td>High intake may mask hematologic evidence of vitamin B12 deficiency</td>
<td>G</td>
<td>Dose and interpretation constraint</td>
<td>The adult tolerable upper intake level is 1,000 µg/day of folic acid from supplements and fortified foods, excluding medically supervised treatment. Folate status and vitamin B12 status should be interpreted together.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br>
<br>
Chemo Interaction Mini-Table<br>
<!-- Folic Acid / Reduced Folates — Chemo Interaction Mini-Table -->
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Drug / Regimen</th>
<th>Folate-Related Agent</th>
<th>Interaction Type</th>
<th>Mechanism (What’s happening)</th>
<th>Clinical Use / Practical Note</th>
<th>Net Effect</th>
</tr>
<tr>
<td><b>High-dose Methotrexate (HD-MTX)</b></td>
<td><b>Leucovorin</b> (folinic acid; calcium folinate)</td>
<td>Rescue (toxicity mitigation)</td>
<td>Provides reduced folate to “rescue” normal cells from MTX-induced reduced-folate depletion; not given simultaneously because it can blunt MTX effect.</td>
<td>Standard component of HD-MTX supportive care (timing is protocol-defined; typically starts after MTX).</td>
<td><b>↓ toxicity</b> while preserving efficacy when timed correctly :contentReference[oaicite:0]{index=0}</td>
</tr>
<tr>
<td><b>5-Fluorouracil (5-FU) regimens</b><br>(e.g., colorectal protocols)</td>
<td><b>Leucovorin</b> (folinic acid)</td>
<td>Potentiation (efficacy enhancement)</td>
<td>Increases and stabilizes thymidylate synthase (TS) inhibition by promoting formation of the inhibitory ternary complex (5-FU metabolite + TS + reduced folate cofactor).</td>
<td>Intentional synergy; also increases risk of GI and marrow toxicity vs 5-FU alone (protocol-dependent).</td>
<td><b>↑ efficacy</b> + often <b>↑ toxicity</b> :contentReference[oaicite:1]{index=1}</td>
</tr>
<tr>
<td><b>Pemetrexed</b> (antifolate chemotherapy)</td>
<td><b>Folic acid</b> (oral) + <b>Vitamin B12</b> (IM)</td>
<td>Required supplementation (toxicity reduction)</td>
<td>Supplementation reduces severity of hematologic and GI toxicity during pemetrexed therapy.</td>
<td>Start before first dose, continue during treatment, and continue after last dose per label/protocol.</td>
<td><b>↓ toxicity</b> (standard of care) :contentReference[oaicite:2]{index=2}</td>
</tr>
<tr>
<td><b>“Folic acid” vs “Leucovorin”</b><br>(naming pitfall)</td>
<td>Folic acid (synthetic) vs Leucovorin (reduced folate)</td>
<td>Non-interchangeable</td>
<td>Leucovorin is a reduced folate used for MTX rescue and 5-FU potentiation; folic acid is mainly a nutritional supplement and not a direct substitute in these oncology protocols.</td>
<td>Use the specific agent indicated by protocol; don’t swap terms in notes.</td>
<td><b>Interpretation / protocol-critical</b> :contentReference[oaicite:3]{index=3}</td>
</tr>
<tr>
<td><b>General supplementation safety note</b></td>
<td>High-dose folic acid supplements</td>
<td>Monitoring issue</td>
<td>Large folate intakes can mask hematologic signs of B12 deficiency while neurologic injury progresses.</td>
<td>Relevant when documenting “high-dose folate” use outside oncology protocols.</td>
<td><b>Safety constraint</b> :contentReference[oaicite:4]{index=4}</td>
</tr>
</table>
<br><br>
<p><b>Alzheimer’s disease relevance:</b> Folic acid is not an established disease-modifying treatment for Alzheimer’s disease. Its strongest neurologic rationale is correction of folate deficiency and reduction of elevated homocysteine, usually in combination with vitamin B12 and sometimes vitamin B6. Randomized studies in mild cognitive impairment indicate that homocysteine-lowering B-vitamin combinations can slow brain atrophy or cognitive decline in selected participants, particularly those with elevated baseline homocysteine; other trials in unselected older adults or established dementia have been neutral. Small trials in mild cognitive impairment or Alzheimer’s disease have reported reductions in inflammatory markers and modest cognitive effects, but these findings are not sufficiently consistent for routine AD treatment recommendations. Vitamin B12 deficiency must be excluded or treated because folic acid can correct anemia while allowing B12-related neurologic injury to progress.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>↓ plasma homocysteine through folate- and vitamin B12-dependent remethylation.</li>
<li>↓ homocysteine-associated vascular, excitotoxic and neurotoxic stress.</li>
<li>Preservation of methylation and phospholipid metabolism during folate deficiency.</li>
<li>Possible ↓ brain atrophy in mild cognitive impairment with elevated homocysteine when used as part of combined B-vitamin therapy.</li>
<li>Possible secondary ↓ inflammatory cytokines and oxidative stress in responsive or deficient populations.</li>
</ol>
<p><b>Clinical evidence status:</b> Small-to-moderate randomized trials and meta-analyses with mixed results. The most credible signal is subgroup-dependent benefit in mild cognitive impairment with elevated homocysteine rather than a general treatment effect in established Alzheimer’s disease.</p>
<h3>Alzheimer’s Disease Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Homocysteine remethylation</td>
<td>↓ homocysteine</td>
<td>G</td>
<td>Metabolic risk-factor reduction</td>
<td>Most reproducible biochemical effect. Clinical relevance is greatest when baseline homocysteine is elevated and vitamin B12 status is adequate.</td>
</tr>
<tr>
<td>2</td>
<td>Brain atrophy</td>
<td>↓ accelerated atrophy (subgroup-dependent)</td>
<td>G</td>
<td>Structural neuroprotection</td>
<td>Observed with combined folic acid, vitamin B12 and vitamin B6 in selected mild cognitive impairment populations; not established for folic acid alone.</td>
</tr>
<tr>
<td>3</td>
<td>Cognitive decline</td>
<td>↓ decline or ↔ (trial-dependent)</td>
<td>G</td>
<td>Possible cognitive preservation</td>
<td>Benefits appear more likely in participants with elevated homocysteine or low B-vitamin status. Several trials in broader populations have been neutral.</td>
</tr>
<tr>
<td>4</td>
<td>Methylation and phospholipid metabolism</td>
<td>↑ methyl-donor support when deficient</td>
<td>G</td>
<td>Neuronal metabolic support</td>
<td>Mechanistically plausible but not a validated surrogate for clinical AD modification.</td>
</tr>
<tr>
<td>5</td>
<td>Neuroinflammation</td>
<td>↓ IL-6, TNF-α and related markers (study-dependent)</td>
<td>G</td>
<td>Secondary anti-inflammatory effect</td>
<td>Reported in several small trials; replication and clinical importance remain uncertain.</td>
</tr>
<tr>
<td>6</td>
<td>Amyloid-related biomarkers</td>
<td>↔ or ↓ (model-dependent)</td>
<td>G</td>
<td>Exploratory biomarker modulation</td>
<td>Human evidence is limited and inconsistent. This should not be classified as established amyloid-targeted therapy.</td>
</tr>
<tr>
<td>7</td>
<td>Oxidative stress</td>
<td>↓ secondary oxidative injury when deficiency or hyperhomocysteinemia is corrected</td>
<td>G</td>
<td>Indirect redox support</td>
<td>Not primarily a direct radical-scavenging mechanism.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>Benefit depends on baseline homocysteine, folate status, vitamin B12 status, disease stage and combined formulation</td>
<td>G</td>
<td>Patient-selection constraint</td>
<td>Evidence from combined B-vitamin regimens cannot be assigned specifically to folic acid. Established dementia has shown less consistent response than selected mild cognitive impairment.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>